Related references
Note: Only part of the references are listed.Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy
Constance Delaugerre et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V
Monique Nijhuis et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance
Carmen de Mendoza et al.
AIDS (2008)
Structural characterization of B and non-B subtypes of HIV-protease: Insights into the natural susceptibility to drug resistance development
Mario Sanches et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Medical care for HIV infection in France in 2005, the NADIS cohort study on 7416 patients
I. Poizot-Martin et al.
MEDECINE ET MALADIES INFECTIEUSES (2006)
Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts
Y Yazdanpanah et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2001)
Share Paper
